Welichem commences enrollment in WBI-1001 Phase IIa clinical trial for psoriasis

Welichem announced that the Company has begun to enroll patients in a Phase IIa clinical trial with its lead candidate, WBI-1001. The Phase IIa clinical trial is a 12-Week, double-blinded, placebo-controlled study. The objectives of the trial are to evaluate the efficacy of the WBI-1001 cream in comparison to the vehicle and also to evaluate the safety and tolerability of the cream in patients with psoriasis.

It is planned that 60 patients (20 placebo and 40 active treatment) will be enrolled in the trial that is anticipated to be concluded in 7 to 9 months.